Top 3 Health Care Stocks You'll Regret Missing In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

• On Nov. 4, Alnylam announced a $1 billion share repurchase program. The company’s stock fell around 27% over the past month and has a 52-week low of $156.00.
• RSI Value: 26.5
• ALNY Price Action: Shares of Alnylam Pharmaceuticals gained 0.7% to close at $161.08 on Wednesday.
• Edge Stock Ratings: 2.83 Momentum score with Value at 59.91.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)        

• On Nov. 3, Madrigal posted upbeat quarterly results. Bill Sibold, Chief Executive Officer of Madrigal, said, “Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.” The company’s stock fell around 19% over the past month and has a 52-week low of $353.54.
• RSI Value: 25.6
• MDGL Price Action: Shares of Madrigal Pharmaceuticals gained 1% to close at $400.43 on Wednesday.
• Benzinga Pro’s charting tool helped identify the trend in MDGL stock.

Corcept Therapeutics Inc (NASDAQ:CORT)

• On Nov. 3, Corcept Therapeutics reported upbeat third-quarter financial results and affirmed its FY26 sales guidance with its midpoint slightly below estimates. “Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.” The company’s stock fell around 35% over the past month and has a 52-week low of $28.66.
• RSI Value: 23.1
• CORT Price Action: Shares of Corcept Therapeutics fell 3.3% to close at $79.22 on Wednesday.
• Benzinga Pro’s signals feature notified of a potential breakout in CORT shares.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock